局部进展期直肠癌单纯应用新辅助化疗研究进展

Value of neoadjuvant chemotherapy alone in locally advanced rectal cancer

近年来,我国局部进展期直肠癌病人的发病率和病死率逐年上升,新辅助放化疗+全直肠系膜切除成为病人的首选治疗方案。新辅助放化疗被认为是局部进展期直肠癌病人的标准治疗方案,但其中放疗并未提高病人的总存活率,且对手术决策和术后恢复方面有不良影响。因此,单纯新辅助化疗的应用价值越来越受到重视,有潜力成为更佳的治疗选择方案。

In recent years,the morbidity and mortality of patients with locally advanced rectal cancer(LARC)have increased year by year.Neoadjuvant therapy plus total mesorectal resection(TME)has become the first choice of treatment in LARC patients.Neoadjuvant chemoradiotherapy is considered as the standard treatment for patients.However,radiotherapy does not increase the overall survival and it has adverse effects on surgical decision-making and postoperative recovery.Therefore,the application value of neoadjuvant chemotherapy alone has been paid more and more attention by scholars and has the potential to become a better treatment option.